about
Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizersSignificant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles.Use of nanoparticles for cerebral cancer.Adsorption of plasma proteins on uncoated PLGA nanoparticles.Transport of drugs across the blood-brain barrier by nanoparticles.Delivery of doxorubicin-loaded PLGA nanoparticles into U87 human glioblastoma cells.Potential of surfactant-coated nanoparticles to improve brain delivery of arylsulfatase A.Simultaneous determination of rifabutin and human serum albumin in pharmaceutical formulations by capillary electrophoresis.Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays.Detection of hepatocellular carcinoma in transgenic mice by Gd-DTPA- and rhodamine 123-conjugated human serum albumin nanoparticles in T1 magnetic resonance imaging.Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.Encapsulation of water-insoluble drugs in poly(butyl cyanoacrylate) nanoparticles.Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles.Transferrin-coated gadolinium nanoparticles as MRI contrast agent.Radiation sterilisation of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles.Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles.Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain.Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants.Contrast enhancement of the brain by folate-conjugated gadolinium-diethylenetriaminepentaacetic acid-human serum albumin nanoparticles by magnetic resonance imaging.Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model.Efficient systemic therapy of rat glioblastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects.Biodistribution of polysorbate 80-coated doxorubicin-loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to glioblastoma-bearing rats.Arylsulfatase A bound to poly(butyl cyanoacrylate) nanoparticles for enzyme replacement therapy--physicochemical evaluation.Development of nanoparticle-bound arylsulfatase B for enzyme replacement therapy of mucopolysaccharidosis VI.Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats.Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma.Toxicological study of doxorubicin-loaded PLGA nanoparticles for the treatment of glioblastomaKinetics of transport of doxorubicin bound to nanoparticles across the blood–brain barrierIncreased Numbers of Injections of Doxorubicin Bound to Nanoparticles Lead to Enhanced Efficacy Against Rat Glioblastoma 101/8Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosisInfluence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: Focus on cardio- and testicular toxicity
P50
Q28478066-5A12561F-3652-4D64-BA2C-927A28DC78FAQ33879575-007298B8-0329-4837-B9C9-640989E28982Q34012338-10FA6B52-365F-4D7C-876C-ACAEE96EC28AQ34581713-07CCB665-681A-42C5-B323-B2239FA8C98DQ37923068-C52268AA-6714-4D24-AE0E-304B5928962CQ38709556-62D6F071-094F-4B21-BA51-71D143586D84Q38953224-BFD1D671-D0FA-48B8-8DAB-AF7C68B8D979Q38991327-3FEBCCF8-CFA4-48F7-B1F6-11B1A6848CBCQ40210994-F50B88CE-7328-47A5-963E-CCE35913FFC2Q41699836-5C70D4E1-EAF4-4895-8BA7-C27F53B1EDAFQ42458746-47D9CA32-877D-45A0-B5C0-957A5F1F9062Q43238142-E2B3F3D2-7F26-4D45-8B85-B1F524E69987Q44386469-F554A6E2-148A-43F6-87B4-F9242F7EB31AQ44767819-DEA0E2D2-0287-4910-9837-FC44D7BD5961Q46737264-47A537B8-C44E-488C-9024-768F6B11E86DQ48003121-60BC7CFD-9972-4B8E-A3DF-16A2037F567DQ48299076-AD1A21D4-2FDA-4283-B4AB-CD357B22D609Q48346110-C4092229-747E-4C19-B8D2-62B88EEF91D8Q48387052-9D73EA80-8404-4E93-8478-0814484D8BC0Q48419354-6D36892C-AD50-496E-98A6-747BB863308BQ48564431-7F499153-EE17-43EB-8925-B741A1C31DC1Q48587255-626B01DD-561D-453C-9A83-DF69E411ECEAQ48630714-37FB02C9-FEA5-4A97-842E-A594B7A6E1DCQ51175979-6EF1BBF0-C92C-4139-BFEB-DC11A27EED4AQ51708880-A2E8D4EF-83E0-4FA8-96D6-A83326893375Q55473881-CEC362AA-F518-4425-A828-0C6321233621Q58595991-93CB18A3-711B-44D2-B13F-774858BFBA62Q62654814-F1D3958A-4232-4362-A25E-D0A4E374E7F0Q62654836-85FF814A-C707-41BE-979E-BAFDD129671AQ62654863-0B70D378-EA29-4F85-A32E-868B56B3501AQ62654869-B3A9F28D-A141-4CC8-8740-6C75B72564FC
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Svetlana Gelperina
@ast
Svetlana Gelperina
@en
Svetlana Gelperina
@es
Svetlana Gelperina
@nl
Svetlana Gelperina
@sl
type
label
Svetlana Gelperina
@ast
Svetlana Gelperina
@en
Svetlana Gelperina
@es
Svetlana Gelperina
@nl
Svetlana Gelperina
@sl
prefLabel
Svetlana Gelperina
@ast
Svetlana Gelperina
@en
Svetlana Gelperina
@es
Svetlana Gelperina
@nl
Svetlana Gelperina
@sl
P106
P1153
6505953995
P21
P31
P496
0000-0003-1113-6715